High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
10 2019
Historique:
received: 01 04 2019
accepted: 07 10 2019
entrez: 1 11 2019
pubmed: 2 11 2019
medline: 6 2 2020
Statut: epublish

Résumé

Whole genome sequencing provides better delineation of transmission clusters in Mycobacterium tuberculosis than traditional methods. However, its ability to reveal individual transmission links within clusters is limited. Here, we used a 2-step approach based on Bayesian transmission reconstruction to (1) identify likely index and missing cases, (2) determine risk factors associated with transmitters, and (3) estimate when transmission happened. We developed our transmission reconstruction method using genomic and epidemiological data from a population-based study from Valencia Region, Spain. Tuberculosis (TB) incidence during the study period was 8.4 cases per 100,000 people. While the study is ongoing, the sampling frame for this work includes notified TB cases between 1 January 2014 and 31 December 2016. We identified a total of 21 transmission clusters that fulfilled the criteria for analysis. These contained a total of 117 individuals diagnosed with active TB (109 with epidemiological data). Demographic characteristics of the study population were as follows: 80/109 (73%) individuals were Spanish-born, 76/109 (70%) individuals were men, and the mean age was 42.51 years (SD 18.46). We found that 66/109 (61%) TB patients were sputum positive at diagnosis, and 10/109 (9%) were HIV positive. We used the data to reveal individual transmission links, and to identify index cases, missing cases, likely transmitters, and associated transmission risk factors. Our Bayesian inference approach suggests that at least 60% of index cases are likely misidentified by local public health. Our data also suggest that factors associated with likely transmitters are different to those of simply being in a transmission cluster, highlighting the importance of differentiating between these 2 phenomena. Our data suggest that type 2 diabetes mellitus is a risk factor associated with being a transmitter (odds ratio 0.19 [95% CI 0.02-1.10], p < 0.003). Finally, we used the most likely timing for transmission events to study when TB transmission occurred; we identified that 5/14 (35.7%) cases likely transmitted TB well before symptom onset, and these were largely sputum negative at diagnosis. Limited within-cluster diversity does not allow us to extrapolate our findings to the whole TB population in Valencia Region. In this study, we found that index cases are often misidentified, with downstream consequences for epidemiological investigations because likely transmitters can be missed. Our findings regarding inferred transmission timing suggest that TB transmission can occur before patient symptom onset, suggesting also that TB transmits during sub-clinical disease. This result has direct implications for diagnosing TB and reducing transmission. Overall, we show that a transition to individual-based genomic epidemiology will likely close some of the knowledge gaps in TB transmission and may redirect efforts towards cost-effective contact investigations for improved TB control.

Sections du résumé

BACKGROUND
Whole genome sequencing provides better delineation of transmission clusters in Mycobacterium tuberculosis than traditional methods. However, its ability to reveal individual transmission links within clusters is limited. Here, we used a 2-step approach based on Bayesian transmission reconstruction to (1) identify likely index and missing cases, (2) determine risk factors associated with transmitters, and (3) estimate when transmission happened.
METHODS AND FINDINGS
We developed our transmission reconstruction method using genomic and epidemiological data from a population-based study from Valencia Region, Spain. Tuberculosis (TB) incidence during the study period was 8.4 cases per 100,000 people. While the study is ongoing, the sampling frame for this work includes notified TB cases between 1 January 2014 and 31 December 2016. We identified a total of 21 transmission clusters that fulfilled the criteria for analysis. These contained a total of 117 individuals diagnosed with active TB (109 with epidemiological data). Demographic characteristics of the study population were as follows: 80/109 (73%) individuals were Spanish-born, 76/109 (70%) individuals were men, and the mean age was 42.51 years (SD 18.46). We found that 66/109 (61%) TB patients were sputum positive at diagnosis, and 10/109 (9%) were HIV positive. We used the data to reveal individual transmission links, and to identify index cases, missing cases, likely transmitters, and associated transmission risk factors. Our Bayesian inference approach suggests that at least 60% of index cases are likely misidentified by local public health. Our data also suggest that factors associated with likely transmitters are different to those of simply being in a transmission cluster, highlighting the importance of differentiating between these 2 phenomena. Our data suggest that type 2 diabetes mellitus is a risk factor associated with being a transmitter (odds ratio 0.19 [95% CI 0.02-1.10], p < 0.003). Finally, we used the most likely timing for transmission events to study when TB transmission occurred; we identified that 5/14 (35.7%) cases likely transmitted TB well before symptom onset, and these were largely sputum negative at diagnosis. Limited within-cluster diversity does not allow us to extrapolate our findings to the whole TB population in Valencia Region.
CONCLUSIONS
In this study, we found that index cases are often misidentified, with downstream consequences for epidemiological investigations because likely transmitters can be missed. Our findings regarding inferred transmission timing suggest that TB transmission can occur before patient symptom onset, suggesting also that TB transmits during sub-clinical disease. This result has direct implications for diagnosing TB and reducing transmission. Overall, we show that a transition to individual-based genomic epidemiology will likely close some of the knowledge gaps in TB transmission and may redirect efforts towards cost-effective contact investigations for improved TB control.

Identifiants

pubmed: 31671150
doi: 10.1371/journal.pmed.1002961
pii: PMEDICINE-D-19-01205
pmc: PMC6822721
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002961

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Mol Biol Evol. 2017 Apr 1;34(4):997-1007
pubmed: 28100788
Lancet Infect Dis. 2018 Jul;18(7):788-795
pubmed: 29681517
Nat Genet. 2013 Oct;45(10):1176-82
pubmed: 23995134
J Immunol. 2018 Nov 1;201(9):2541-2548
pubmed: 30348659
N Engl J Med. 2018 Jan 18;378(3):221-229
pubmed: 29342390
EBioMedicine. 2018 Aug;34:4-5
pubmed: 30072212
Int J Tuberc Lung Dis. 1997 Aug;1(4):352-7
pubmed: 9432392
PLoS Pathog. 2018 Feb 8;14(2):e1006885
pubmed: 29420641
J Infect Dis. 2017 Aug 1;216(3):366-374
pubmed: 28666374
J Infect Dis. 2015 Apr 15;211(8):1306-16
pubmed: 25362193
N Engl J Med. 2011 Feb 24;364(8):730-9
pubmed: 21345102
PLoS One. 2018 Apr 4;13(4):e0195413
pubmed: 29617456
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
PLoS Comput Biol. 2016 Sep 28;12(9):e1005130
pubmed: 27681228
Mol Biol Evol. 2019 Mar 1;36(3):587-603
pubmed: 30690464
J Clin Microbiol. 2015 Jun;53(6):1908-14
pubmed: 25854485
Sci Adv. 2019 Jun 12;5(6):eaaw3307
pubmed: 31448322
Genome Biol. 2014 Mar 03;15(3):R46
pubmed: 24580807
EBioMedicine. 2018 Aug;34:122-130
pubmed: 30077721
Eur Respir J. 2015 Apr;45(4):928-52
pubmed: 25792630
Elife. 2018 Oct 30;7:
pubmed: 30373719
Clin Infect Dis. 2008 Nov 1;47(9):1135-42
pubmed: 18823268
Lancet Respir Med. 2014 Apr;2(4):251-2
pubmed: 24717616
Clin Microbiol Rev. 2018 Jul 18;31(4):
pubmed: 30021818
PLoS Comput Biol. 2015 Dec 30;11(12):e1004613
pubmed: 26717515
Lancet Respir Med. 2019 Mar;7(3):199-201
pubmed: 30823971
Nat Rev Microbiol. 2019 Sep;17(9):533-545
pubmed: 31209399
J Infect Dis. 2019 Jun 19;220(2):316-320
pubmed: 30875421
PLoS Med. 2013;10(2):e1001387
pubmed: 23424287
Nat Rev Microbiol. 2009 Dec;7(12):845-55
pubmed: 19855401
Am J Respir Crit Care Med. 2013 Mar 1;187(5):543-51
pubmed: 23262515
Microb Genom. 2016 Nov 30;2(11):e000094
pubmed: 28348834
Lancet Respir Med. 2018 Apr;6(4):244-246
pubmed: 29595504
PLoS Comput Biol. 2017 May 18;13(5):e1005495
pubmed: 28545083
Eur Respir J. 2017 Dec 28;50(6):
pubmed: 29284687
BMC Med. 2016 Mar 23;14:21
pubmed: 27005433
PLoS Pathog. 2019 Sep 12;15(9):e1008067
pubmed: 31513651
Lancet Respir Med. 2014 Apr;2(4):285-292
pubmed: 24717625
PLoS One. 2009 Nov 12;4(11):e7815
pubmed: 19915672
Lancet. 1999 Feb 6;353(9151):444-9
pubmed: 9989714
Elife. 2015 Mar 03;4:null
pubmed: 25732036
PLoS One. 2015 Jul 16;10(7):e0132840
pubmed: 26181760

Auteurs

Yuanwei Xu (Y)

Centre for Mathematics of Precision Healthcare, Department of Mathematics, Imperial College London, London, United Kingdom.

Irving Cancino-Muñoz (I)

Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.

Manuela Torres-Puente (M)

Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.

Luis M Villamayor (LM)

Genomics and Health Unit, FISABIO Public Health, Valencia, Spain.

Rafael Borrás (R)

Microbiology Service, Hospital Clínico Universitario, Valencia, Spain.

María Borrás-Máñez (M)

Microbiology and Parasitology Service, Hospital Universitario de La Ribera, Alzira, Spain.

Montserrat Bosque (M)

Microbiology Service, Hospital Arnau de Vilanova, Valencia, Spain.

Juan J Camarena (JJ)

Microbiology Service, Hospital Universitario Dr. Peset, Valencia, Spain.

Ester Colomer-Roig (E)

Genomics and Health Unit, FISABIO Public Health, Valencia, Spain.
Microbiology Service, Hospital Universitario Dr. Peset, Valencia, Spain.

Javier Colomina (J)

Microbiology and Parasitology Service, Hospital Universitario de La Ribera, Alzira, Spain.

Isabel Escribano (I)

Microbiology Laboratory, Hospital Virgen de los Lírios, Alcoy, Spain.

Oscar Esparcia-Rodríguez (O)

Microbiology Service, Hospital de Denia, Denia, Spain.

Ana Gil-Brusola (A)

Microbiology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Concepción Gimeno (C)

Microbiology Service, Hospital General Universitario de Valencia, Valencia, Spain.

Adelina Gimeno-Gascón (A)

Microbiology Service, Hospital General Universitario de Alicante, Alicante, Spain.

Bárbara Gomila-Sard (B)

Microbiology Service, Hospital General Universitario de Castellón, Castellon, Spain.

Damiana González-Granda (D)

Microbiology Service, Hospital Lluís Alcanyis, Xativa, Spain.

Nieves Gonzalo-Jiménez (N)

Microbiology Service, Hospital General Universitario de Elche, Elche, Spain.

María Remedio Guna-Serrano (MR)

Microbiology Service, Hospital General Universitario de Valencia, Valencia, Spain.

José Luis López-Hontangas (JL)

Microbiology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Coral Martín-González (C)

Microbiology Service, Hospital Universitario de San Juan de Alicante, Alicante, Spain.

Rosario Moreno-Muñoz (R)

Microbiology Service, Hospital General Universitario de Castellón, Castellon, Spain.

David Navarro (D)

Microbiology Service, Hospital Clínico Universitario, Valencia, Spain.

María Navarro (M)

Microbiology Service, Hospital de la Vega Baixa, Orihuela, Spain.

Nieves Orta (N)

Microbiology Service, Hospital San Francesc de Borja, Gandía, Spain.

Elvira Pérez (E)

Subdirección General de Epidemiología y Vigilancia de la Salud, Dirección General de Salud Pública, Valencia, Spain.

Josep Prat (J)

Microbiology Service, Hospital de Sagunto, Sagunto, Spain.

Juan Carlos Rodríguez (JC)

Microbiology Service, Hospital General Universitario de Alicante, Alicante, Spain.

María Montserrat Ruiz-García (MM)

Microbiology Service, Hospital Lluís Alcanyis, Xativa, Spain.

Herme Vanaclocha (H)

Subdirección General de Epidemiología y Vigilancia de la Salud, Dirección General de Salud Pública, Valencia, Spain.

Caroline Colijn (C)

Centre for Mathematics of Precision Healthcare, Department of Mathematics, Imperial College London, London, United Kingdom.
Department of Mathematics, Simon Fraser University, Burnaby, British Columbia, Canada.

Iñaki Comas (I)

Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH